含硼药物的研究进展  

Research progress of boron-containing drugs

作　　者：杜丰华 董正川 陈乐园 侯文彬 李祎亮[3] DU Fenghua;DONG Zhengchuan;CHEN Leyuan;HOU Wenbin;LI Yiliang(Tianjin University of Traditional Chinese Medicine,Tianjin 301617;Tianjin Chase Sun Pharmaceutical Co.,Ltd.,Tianjin 301700;Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Radiation Medicine,Tianjin Municipal Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine,Tianjin 300192,China)

机构地区：[1]天津中医药大学,天津301617 [2]天津红日药业股份有限公司,天津301700 [3]中国医学科学院北京协和医学院放射医学研究所,天津市放射医学与分子核医学重点实验室,天津300192

出　　处：《中国药科大学学报》2023年第2期159-171,共13页Journal of China Pharmaceutical University

基　　金：国家自然科学基金青年项目资助(No.82104012);中国医学科学院医学与健康科技创新工程重大协同创新项目资助(No.2021-I2M-1-042)。

摘　　要：近年来,关于含硼药物,尤其是硼酸类药物的研究逐渐增多。含硼药物代表了药物化学家在研发领域开拓的一类新成果,这类药物在抗炎、抗菌、抗肿瘤等方面正扮演着愈发重要的角色。目前,全球已有5个含硼药物获批上市,正处于临床试验阶段的含硼药物也不在少数,同时近几年在研新药的不断出现,极大地扩展了硼在药物研发领域的应用。本文通过介绍硼元素的特性,并对处于各个研究阶段的代表性含硼药物的适应证,与靶点的结合机制,以及它们进入临床试验后的进展进行综述,以期为含硼药物的进一步研究提供参考。In recent years,the research on boron-containing drugs,especially boric acid drugs,has been increasing gradually.Boron-containing drugs,which have been a new area of research for pharmaceutical chemists in the development of new drugs,play an increasingly important anti-inflammatory,antibacterial,and anti-tumor role.At present,five boron-containing drugs have been approved,many are under clinical trials,and more are under investigation around the world,which has greatly expanded the application of boron in the research of new drugs.This paper introduces the characteristics of boron,and reviews the indications of representative boron-containing drugs in various research stages,their binding mechanisms with targets,and their progress after entering clinical trials,aiming to provide reference for further research on boron-containing drugs.

关 键 词：含硼化合物 上市药物 共价抑制 药物靶标 临床试验 

分 类 号：R914[医药卫生—药物化学]